Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of Senate Bill 997 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of House Bill 1204 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the notice titled “Advance Summary of Methodological Changes for Calendar Year (CY) 2018 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2018 Call Letter” released on February 1, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the notice titled “Advance Summary of Methodological Changes for Calendar Year (CY) 2018 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2018 Call Letter” released on February 1, 2017.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of Senate Bill 92 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of Senate Bill No. 32 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of House Bill 82 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of Senate Bill No. 32 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of LB 481 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
AMCP supports a coalition of over 20 health care stakeholders committed to aligning 42 CFR Part 2 (part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.
The Partnership to Amend 42 CFR Part 2, a coalition of nearly 30 health care organizations committed to aligning the Substance Abuse and Mental Health Service Administration's (SAMHSA) final rule on Confidentiality of Alcohol and Drug Abuse Patient Records, 42 Code of Federal Regulations Part 2 (Part 2) with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) to allow appropriate access to patient information that is essential for providing whole-person care, issued the following statement in response to the Part 2 final rule.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments on the notice titled “CMS-10396 Medication Therapy Management Program Improvements” published in the Federal Register on October 31, 2016. Under the notice, the Medicare Part D Medication Therapy Management (MTM) Program Standardized Format (“standardized format”) would be reauthorized in its current format for an additional three years through 2020.
